Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
E-Cigarette Smoke Poses Threat to DNA Repair Activity
February 1st 2018

E-Cigarette Smoke Poses Threat to DNA Repair Activity

Kaitlynn Ely
E-cigarette smokers have a high risk of developing lung and bladder cancer, as well as certain heart diseases due to carcinogenic e-cigarette smoke (ECS), according to a study published in the Proceedings of the National Academy of Sciences.
Site Logo
February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

AJMC®tv Interviews, January 2018

At the American Society of Hematology’s 59th Annual Meeting and Exposition, healthcare industry leaders sat down with The American Journal of Managed Care® to speak about what’s new and important about changes in healthcare. Access the video clips at ajmc.com/conferences/ash-2017.
Site Logo
February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Biosimilars Update

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
January 31st 2018

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options
January 31st 2018

Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options

Samantha DiGrande
The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
January 31st 2018

Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development

Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
CAR T-Cell Therapy Named ASCO's Advance of the Year
January 31st 2018

CAR T-Cell Therapy Named ASCO's Advance of the Year

Jaime Rosenberg
Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in ASCO’s Clinical Cancer Advances 2018. According to the annual report, CAR T-cell therapy is “poised to transform the outlook for children and adults with certain otherwise incurable cancers."
Site Logo
January 30th 2018

Analysis Shows Majority of Hospitals Will See Payment Increases Despite 340B Payment Cuts

Jaime Rosenberg
As a result of the Medicare Outpatient Prospective Payment System rule that took effect on January 1, 85% of 340B hospitals will see net payment increases in 2018. Rural hospitals will reap the largest benefits, according to an analysis conducted by Avalere and commissioned by Community Oncology Alliance.
Nat Turner: Data Can Disrupt Clinical Research and Improve Patient Care
January 30th 2018

Nat Turner: Data Can Disrupt Clinical Research and Improve Patient Care

Nat Turner, co-founder and CEO of Flatiron Health, explains how data can be used for finding potential patients to be included in clinical trials.
Scientists Develop Tool to Analyze Links Between Lifestyle Choices and Certain Cancers
January 30th 2018

Scientists Develop Tool to Analyze Links Between Lifestyle Choices and Certain Cancers

Kaitlynn Ely
A team of 20 scientists in the fields of informatics, statistics, epidemiology, systematic reviews, cancer biology, and nutrition have developed a tool that will assess the links in published human studies between lifestyle factors and cancer.
Using Health IT to Increase Medication Adherence and Enhance Precision Medicine
January 30th 2018

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Jaime Rosenberg
As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.
Oncologists Overcome Hurdles to Deliver Cancer Care in Puerto Rico
January 29th 2018

Oncologists Overcome Hurdles to Deliver Cancer Care in Puerto Rico

Allison Inserro
Even though much more remains to be done on an island where half of its US residents still lack power, the situation is improving for cancer patients in Puerto Rico, doctors and organizations said recently in interviews with The American Journal of Managed Care®. In Puerto Rico, more than 75% of the cancer care is delivered in the community, not hospitals.
Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology
January 29th 2018

Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology

When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
ASCO Provides CMS Recommendations on Revisions to Part D
January 28th 2018

ASCO Provides CMS Recommendations on Revisions to Part D

Kaitlynn Ely
The American Society of Clinical Oncology (ASCO) recommends that CMS guard cancer patients from high out-of-pocket costs that will impede patient access to life-extending cancer drugs, according to the society’s comments regarding proposed financial revisions to the Medicare Prescription Drug Benefit Program (Part D).
Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer
January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA
Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
Bo Gamble Explains How COA Helps Practices Prepare for OCM
January 27th 2018

Bo Gamble Explains How COA Helps Practices Prepare for OCM

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), explains how COA plays a role in supporting practices in preparing for Oncology Care Model.
Via Oncology Acquisition Positions Pathway Provider for Growth
January 26th 2018

Via Oncology Acquisition Positions Pathway Provider for Growth

Mary Caffrey
Via Pathways covers more than 2000 different patient representations in cancer care.
Study Notes Racial Differences in Risk of Recurrence Among Patients With Breast Cancer
January 26th 2018

Study Notes Racial Differences in Risk of Recurrence Among Patients With Breast Cancer

Kaitlynn Ely
Non-Hispanic black women diagnosed with HER2-negative, lymph node-negative breast cancer who had recurrence score testing had higher estimated risks of distant recurrence than their non-Hispanic white counterparts.
High Cost Sharing Associated With Reduced Access to Targeted Therapies for Patients With mRCC
January 25th 2018

High Cost Sharing Associated With Reduced Access to Targeted Therapies for Patients With mRCC

Jaime Rosenberg
High cost sharing is associated with reduced and/or delayed access to targeted therapies under Medicare Part D for patients with metastatic renal cell carcinoma, suggesting that financial barriers play a significant role in treatment decisions, according to a study published in Cancer Medicine.
Patients Prefer End-of-Life Care in Their Location of Choice
January 24th 2018

Patients Prefer End-of-Life Care in Their Location of Choice

Kaitlynn Ely
Patients diagnosed with cancer want their doctors to ask them their desire location for end-of-life (EOL) care, according to a recent study published in the Journal of the National Comprehensive Cancer Network.
Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models
January 24th 2018

Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models

Over the next years, these spheres (ACOs, primary care, and oncology) that are going on in CMMI need to be coalesced together so that when we have learning collaboratives, not only do we have learning collaboratives within each of these spheres, but we learn from each other in these similar projects, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM
January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA
The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Site Logo
January 22nd 2018

The Fallacy of Estimating OCM Target Prices

Darcie Hurteau
Estimating episodic target prices for each patient in the Oncology Care Model (OCM) can be challenging and time consuming. Applying that time to quality-focused care management tactics, based on observed utilization and patient outcomes, may wind up being more valuable, and help to reduce unnecessary spending.
Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse
January 20th 2018

Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse

Samantha DiGrande
Researchers at The University of Texas MD Anderson Cancer Center recently reported in Lancet Oncology that a pair of targeted therapies given before and after surgery for melanoma produced a 6-fold increase in time to progression of the disease, compared with standard-of-care surgery for patients with stage 3 melanoma.
Podcast: This Week in Managed Care—Kentucky's Medicaid Work Requirement and Other Health News
January 20th 2018

Podcast: This Week in Managed Care—Kentucky's Medicaid Work Requirement and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
<1
...
565758596061626364
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo